Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...

Jan. 7, 2025 /PRNewswire/ -- After two inspiring nights of preliminary competition, during which 52 delegates from across the United States and ... advocate for Cystic Fibrosis, Abbie was named ...

The studies are evaluating ARCT-032 for cystic fibrosis in a Phase 2 trial and ARCT-810 for ornithine transcarbamylase (OTC) deficiency in a Phase 2a study in the United States. The "LunairCF ...

There are close to 40,000 children and adults living with cystic fibrosis in the United States (and an estimated 105,000 people have been diagnosed with CF across 94 countries), and CF can affect ...

Tennessee who is battling cystic fibrosis. BRENTWOOD, Tenn., November 18, 2024--Tractor Supply Company (NASDAQ: TSCO), the largest rural lifestyle retailer in the United States, has released a ...

While there are currently 13 clinical trial sites for RCT2100 throughout the country, this was the first dose to be successfully administered in the United States. “This milestone represents a pivotal ...

Eli Lilly has also increased its research and development (R&D) budget substantially — having spent as much as $9 billion for a single manufacturing facility in the United States ... revenue from ...

I spent my childhood and young adulthood being told I was “too young and healthy” to be dealing with the health issues I experienced. But as an adult, I was determined to find answers, and eventually, ...

Anagram Therapeutics is a client of Epicured's Life Sciences Division dedicated to advancing scientific research through thoughtful integration of nutrition in study protocols. Participants in ...

The United States market has shown robust performance recently, climbing 3.0% in the last week and achieving a 25% increase over the past year, with earnings expected to grow by 15% annually.

In December, the FDA approved Vertex’s vanzacaftor, tezacaftor and deutivacaftor (Alyftrek) for the treatment of cystic fibrosis in patients with at least one F508del mutation or another ...